Updates are available Correction dated 2021-04-29
Click to view Correction: https://doi.org/10.1007/s11481-021-09992-5
-
Authors
Nedelcovych, Michael T.
Kim, Boe-Hyun
Zhu, Xiaolei
Lovell, Lyndah E.
Manning, Arena A.
Kelschenbach, Jennifer
Hadas, Eran
Chao, Wei
Prchalová, Eva
Dash, Ranjeet P.
Wu, Ying
Alt, Jesse
Thomas, Ajit G.
Rais, Rana
Kamiya, Atsushi
Volsky, David J.
Slusher, Barbara S.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (P30MH075673)
National Institute of Mental Health (R01MH105145)
National Institute of Mental Health (R25MH080661)
National Cancer Institute (R01CA193895)
National Institute on Drug Abuse (R01DA037611)
National Institute on Drug Abuse (R01DA041208)
National Institute of General Medical Sciences (R25GM109441)
Pharmaceutical Research and Manufacturers of America Foundation (Postdoctoral Fellowship in Pharmacology/Toxicology)
TEDCO (MII)
- License Information
-
More Information
Article History
Received: 27 February 2019
Accepted: 28 May 2019
First Online: 17 June 2019
Change Date: 29 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11481-021-09992-5
Compliance with Ethical Standards
:
: Under a license agreement between Dracen Pharmaceuticals, Inc. and the Johns Hopkins University, B.S.S., R.R., and J.A. are entitled to royalty distributions related to technology used in the research described in this publication. B.S.S. and R.R. are also co-founders of and hold equity in Dracen Pharmaceuticals, Inc. which is clinically developing glutamine antagonist prodrugs. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. B.S.S., D.J.V., M.T.N. and A.K. are also inventors on a patent application relevant to the research in this publication.
